A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone

References

• Barnes TR, Curson DA. Long-term depot antipsychotics. A risk-benefit assessment. Drug Saf 1994; 10: 464–479
   PubMed Web of Science ®Google Scholar
• Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004; 14: 87–92
   PubMed Web of Science ®Google Scholar
• Colom F, Vieta E, Reinares M, et al. Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. J Clin Psychiatry 2003; 64: 1101–1105
   PubMed Web of Science ®Google Scholar
• Esparon J, Kolloori J, Naylor GJ, McHarg AM, Smith AH, Hopwood SE. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986; 148: 723–725
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Lemmens P, van Baelen B. A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database. Pharmacopsychiatry 2001; 34: 104–110
   PubMedGoogle Scholar
• Ghaemi SN, Hsu DJ, Rosenquist KJ, Katzow JJ, Goodwin FK. Long-term observational comparison of risperidone and olanzapine in bipolar disorder. Ann Clin Psychiatry 2004; 16: 69–73
   PubMedGoogle Scholar
• Gurovich I, Kobina S, Lyubov E. A pharmacoeconomic analyses of depot neuroleptic treatment in natural setting. Value Health 2001; 3: 79
   Google Scholar
• Guy W. (Ed.). 1976. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology, revised. National Institute of Mental Health, Rockville, MD.
   Google Scholar
• Harvey PD, Green MF, McGurk SR, Meltzer HY. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berlin) 2003; 169: 404–411
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Eerdekens M, Kalali AH, et al. An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder. Int Clin Psychopharmacol 2006; 21: 11–20
   PubMedGoogle Scholar
• Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125–1132
   PubMed Web of Science ®Google Scholar
• Keck PE, Jr, McElroy SL, Strakowski SM, et al. 12–month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998; 155: 646–652
   PubMed Web of Science ®Google Scholar
• Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 2006; 81: 1–15
   PubMed Web of Science ®Google Scholar
• Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study. Br J Psychiatry 2005; 187: 229–234
   PubMed Web of Science ®Google Scholar
• Leal A, Rosillon D, Mehnert A, Jarema M, Remington G. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf 2004; 13: 811–816
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Jarboe K, Bossie CA, Zhu Y, Mehnert A, Lasser R. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol 2005; 20: 213–221
   PubMed Web of Science ®Google Scholar
• Lowe MR, Batchelor DH. Depot neuroleptics and manic depressive psychosis. Int Clin Psychopharmacol 1986; 1(Suppl. 1)53–62
   PubMedGoogle Scholar
• Marken PA, Stanislav SW, Lacombe S, Pierce C, Hornstra R, Sommi RW. Profile of a sample of subjects admitted to an acute care psychiatric facility with manic symptoms. Psychopharmacol Bull 1992; 28: 201–205
   PubMedGoogle Scholar
• Nayak RK, Doose DR, Nair NP. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol 1987; 27: 144–150
   PubMed Web of Science ®Google Scholar
• Reinares M, Martinez-Aran A, Colom F, Benabarre A, Salamero M, Vieta E. Long-term effects of the treatment with risperidone versus conventional neuroleptics on the neuropsychological performance of euthymic bipolar patients]. Actas Esp Psiquiatr 2000; 28: 231–238
   PubMed Web of Science ®Google Scholar
• Schumann C, Lenz G, Berghofer A, Muller-Oerlinghausen B. Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients. Psychiatry Res 1999; 89: 247–257
   PubMed Web of Science ®Google Scholar
• Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 2002; 63: 384–390
   PubMed Web of Science ®Google Scholar
• Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001; 52: 805–811
   PubMed Web of Science ®Google Scholar
• Vieta E, Rosa AR. Evolving trends in the long-term treatment of bipolar disorder. World J Biol Psychiatry 2007; 8: 4–11
   PubMed Web of Science ®Google Scholar
• Vieta E, Herraiz M, Fernandez A, et al. Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD). J Clin Psychiatry 2001; 62: 623–630
   PubMed Web of Science ®Google Scholar
• Vieta E, Herraiz M, Parramon G, Goikolea JM, Fernandez A, Benabarre A. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. J Affect Disord 2002; 72: 15–19
   PubMed Web of Science ®Google Scholar
• Vieta E, Goikolea JM, Olivares JM, et al. 1-year follow-up of patients treated with risperidone and topiramate for a manic episode. J Clin Psychiatry 2003; 64: 834–839
   PubMedGoogle Scholar
• Vieta E, Brugue E, Goikolea JM, et al. Acute and continuation risperidone monotherapy in mania. Hum Psychopharmacol 2004; 19: 41–45
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419–429
   PubMed Web of Science ®Google Scholar
• White E, Cheung P, Silverstone P. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993; 8: 119–122
   PubMed Web of Science ®Google Scholar